Trial Profile
A prospective, multicentre, open-label, post-marketing study to evaluate the safety and efficacy of ripasudil in patients with glaucoma (including SG) or Ocular Hypertension over 2 years
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Ripasudil (Primary)
- Indications Angle-closure glaucoma; Glaucoma; Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ROCK-J
- 12 Feb 2022 Results (n=3374) assessing the long-term safety and effectiveness of ripasudil in Japanese patients with glaucoma or ocular hypertension, published in the Advances in Therapy.
- 08 Feb 2019 New trial record
- 04 Jan 2019 Three month interim results (n=3058 safety analysis, n=3016 efficacy analysis) published in the Advances in Therapy